Balanced two-stage designs for phase II clinical trials

被引:17
|
作者
Ye, Fei [1 ]
Shyr, Yu [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Biostat, Div Canc Biostat, Nashville, TN 37203 USA
关键词
D O I
10.1177/1740774507084102
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Oncology phase II clinical trials are often designed using Simon's two-stage designs (optimal and 'minimax') for independent observations. Simon's designs do not include the use of correlated observations, and do not balance the sample sizes of the two stages. In these designs, the sample sizes of the two stages can be highly unequal. In certain circumstances, an alternative design option that balances the sample sizes is desirable. Purpose To develop a two-stage phase II design that balances the sample sizes of the first and the second stages, while controlling for type I and type II error rates. Methods We simulated designs based on response rates under various null and alternative hypotheses, type I and type II error constraints, and the degree of correlation in the case of correlated data. For correlated data, Sargent's method is adopted to account for the loss of information due to intra-person correlation. Results Design characteristics for different parameter settings were generated using balanced design method, separately for independent and correlated data. Results were evaluated and compared to the optimal and minimax design. Limitations For correlated data, designs were produced only for trials with half of the participants having one observation and the other half having two. Also, the degree of intra-person correlation was fixed at three levels. Conclusion The balanced design provides an additional choice for two-stage phase 11 trials when the investigators would like to monitor the trial near a study's halfway point. Meanwhile, its total sample sizes are comparable with Simon's designs.
引用
收藏
页码:514 / 524
页数:11
相关论文
共 50 条
  • [31] Two-stage designs in bioequivalence trials
    Schuetz, Helmut
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (03) : 271 - 281
  • [32] A design alternative for two-stage, phase II, multicenter cancer clinical trials
    Herndon, JE
    [J]. CONTROLLED CLINICAL TRIALS, 1998, 19 (05): : 440 - 450
  • [33] Improved two-stage tests for stratified phase II cancer clinical trials
    Chang, Myron N.
    Shuster, Jonathan J.
    Hou, Wei
    [J]. STATISTICS IN MEDICINE, 2012, 31 (16) : 1688 - 1698
  • [34] Incorporating toxicity considerations into the design of two-stage Phase II clinical trials
    Bryant, J
    Day, R
    [J]. BIOMETRICS, 1995, 51 (04) : 1372 - 1383
  • [35] Exact two-stage designs for phase II activity trials with rank-based endpoints
    Wilding, Gregory E.
    Shan, Guogen
    Hutson, Alan D.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2012, 33 (02) : 332 - 341
  • [36] What inference for two-stage phase II trials?
    Porcher, Raphael
    Desseaux, Kristell
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2012, 12
  • [37] What inference for two-stage phase II trials?
    Raphaël Porcher
    Kristell Desseaux
    [J]. BMC Medical Research Methodology, 12
  • [38] Adaptive two-stage designs for single-arm phase IIA cancer clinical trials
    Lin, Y
    Shih, WJ
    [J]. BIOMETRICS, 2004, 60 (02) : 482 - 490
  • [39] Two-stage designs for Phase 2 dose-finding trials
    Ivanova, Anastasia
    Xiao, Changfu
    Tymofyeyev, Yevgen
    [J]. STATISTICS IN MEDICINE, 2012, 31 (24) : 2872 - 2881
  • [40] Optimal Two-stage Designs for Single-arm Phase II Oncology Trials with Two Binary Endpoints
    Kunz, C. U.
    Kieser, M.
    [J]. METHODS OF INFORMATION IN MEDICINE, 2011, 50 (04) : 372 - 377